Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics
Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors...
Gespeichert in:
| Veröffentlicht in: | Progress in neurology and psychiatry (Guildford) 2019-07, Vol.23 (3), p.26-33 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 3 |
| container_start_page | 26 |
| container_title | Progress in neurology and psychiatry (Guildford) |
| container_volume | 23 |
| creator | Krishnaswamy, Ratna Malik, Bilal Haider Khan, Safeera Gupta, Deepti Islam, Muhammad Mandal, Shrawan Kumar Rutkofsky, Ian H |
| description | Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti‐CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it. |
| doi_str_mv | 10.1002/pnp.544 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2328313995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2328313995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3224-e9db5ccefc3978628284bdb3b1e9ce8155ea006b1ef1ad93125901c4df02b3d93</originalsourceid><addsrcrecordid>eNp1kM1KAzEQx4MoWKv4CgsePMjWfGz2w1sptRWKFlHwFpLsbJu63azJLtKbj-Az-iSm1KunmfnzY5j5IXRJ8IhgTG_bph3xJDlCA1IwElOavR2HnqVZnPGEnaIz7zcYc55yPkDzcdOZn6_vyex5GW1tY3VtG1lHMsTKlgb8XaQcyPdu7Wy_WkemibZm5aRpIOrW4GQLfWe0P0cnlaw9XPzVIXq9n75M5vHiafYwGS9izShNYihKxbWGSrMiy1Oa0zxRpWKKQKEhJ5yDxDgNY0VkGR6gvMBEJ2WFqWIhGKKrw97W2Y8efCc2tnfhZC8oozkjrCh4oK4PlHbWeweVaJ3ZSrcTBIu9JhE0iaApkDcH8tPUsPsPE8vH5Z7-BTahac0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2328313995</pqid></control><display><type>article</type><title>Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Krishnaswamy, Ratna ; Malik, Bilal Haider ; Khan, Safeera ; Gupta, Deepti ; Islam, Muhammad ; Mandal, Shrawan Kumar ; Rutkofsky, Ian H</creator><creatorcontrib>Krishnaswamy, Ratna ; Malik, Bilal Haider ; Khan, Safeera ; Gupta, Deepti ; Islam, Muhammad ; Mandal, Shrawan Kumar ; Rutkofsky, Ian H</creatorcontrib><description>Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti‐CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it.</description><identifier>ISSN: 1367-7543</identifier><identifier>EISSN: 1931-227X</identifier><identifier>DOI: 10.1002/pnp.544</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Migraine ; Monoclonal antibodies</subject><ispartof>Progress in neurology and psychiatry (Guildford), 2019-07, Vol.23 (3), p.26-33</ispartof><rights>Copyright © 2019 John Wiley & Sons, Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3224-e9db5ccefc3978628284bdb3b1e9ce8155ea006b1ef1ad93125901c4df02b3d93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Krishnaswamy, Ratna</creatorcontrib><creatorcontrib>Malik, Bilal Haider</creatorcontrib><creatorcontrib>Khan, Safeera</creatorcontrib><creatorcontrib>Gupta, Deepti</creatorcontrib><creatorcontrib>Islam, Muhammad</creatorcontrib><creatorcontrib>Mandal, Shrawan Kumar</creatorcontrib><creatorcontrib>Rutkofsky, Ian H</creatorcontrib><title>Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics</title><title>Progress in neurology and psychiatry (Guildford)</title><description>Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti‐CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it.</description><subject>Migraine</subject><subject>Monoclonal antibodies</subject><issn>1367-7543</issn><issn>1931-227X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEQx4MoWKv4CgsePMjWfGz2w1sptRWKFlHwFpLsbJu63azJLtKbj-Az-iSm1KunmfnzY5j5IXRJ8IhgTG_bph3xJDlCA1IwElOavR2HnqVZnPGEnaIz7zcYc55yPkDzcdOZn6_vyex5GW1tY3VtG1lHMsTKlgb8XaQcyPdu7Wy_WkemibZm5aRpIOrW4GQLfWe0P0cnlaw9XPzVIXq9n75M5vHiafYwGS9izShNYihKxbWGSrMiy1Oa0zxRpWKKQKEhJ5yDxDgNY0VkGR6gvMBEJ2WFqWIhGKKrw97W2Y8efCc2tnfhZC8oozkjrCh4oK4PlHbWeweVaJ3ZSrcTBIu9JhE0iaApkDcH8tPUsPsPE8vH5Z7-BTahac0</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Krishnaswamy, Ratna</creator><creator>Malik, Bilal Haider</creator><creator>Khan, Safeera</creator><creator>Gupta, Deepti</creator><creator>Islam, Muhammad</creator><creator>Mandal, Shrawan Kumar</creator><creator>Rutkofsky, Ian H</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20190701</creationdate><title>Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics</title><author>Krishnaswamy, Ratna ; Malik, Bilal Haider ; Khan, Safeera ; Gupta, Deepti ; Islam, Muhammad ; Mandal, Shrawan Kumar ; Rutkofsky, Ian H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3224-e9db5ccefc3978628284bdb3b1e9ce8155ea006b1ef1ad93125901c4df02b3d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Migraine</topic><topic>Monoclonal antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krishnaswamy, Ratna</creatorcontrib><creatorcontrib>Malik, Bilal Haider</creatorcontrib><creatorcontrib>Khan, Safeera</creatorcontrib><creatorcontrib>Gupta, Deepti</creatorcontrib><creatorcontrib>Islam, Muhammad</creatorcontrib><creatorcontrib>Mandal, Shrawan Kumar</creatorcontrib><creatorcontrib>Rutkofsky, Ian H</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Progress in neurology and psychiatry (Guildford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krishnaswamy, Ratna</au><au>Malik, Bilal Haider</au><au>Khan, Safeera</au><au>Gupta, Deepti</au><au>Islam, Muhammad</au><au>Mandal, Shrawan Kumar</au><au>Rutkofsky, Ian H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics</atitle><jtitle>Progress in neurology and psychiatry (Guildford)</jtitle><date>2019-07-01</date><risdate>2019</risdate><volume>23</volume><issue>3</issue><spage>26</spage><epage>33</epage><pages>26-33</pages><issn>1367-7543</issn><eissn>1931-227X</eissn><abstract>Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti‐CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/pnp.544</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1367-7543 |
| ispartof | Progress in neurology and psychiatry (Guildford), 2019-07, Vol.23 (3), p.26-33 |
| issn | 1367-7543 1931-227X |
| language | eng |
| recordid | cdi_proquest_journals_2328313995 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Migraine Monoclonal antibodies |
| title | Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T21%3A30%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90CGRP%20monoclonal%20antibodies:%20breakthrough%20in%20migraine%20therapeutics&rft.jtitle=Progress%20in%20neurology%20and%20psychiatry%20(Guildford)&rft.au=Krishnaswamy,%20Ratna&rft.date=2019-07-01&rft.volume=23&rft.issue=3&rft.spage=26&rft.epage=33&rft.pages=26-33&rft.issn=1367-7543&rft.eissn=1931-227X&rft_id=info:doi/10.1002/pnp.544&rft_dat=%3Cproquest_cross%3E2328313995%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2328313995&rft_id=info:pmid/&rfr_iscdi=true |